Linderane 是一种口服有效且可穿过血脑屏障的天然倍半萜内酯,它通过激活 ERK/STAT3 间接激活 PDE3,进而抑制 cAMP/PKA/CREB 信号通路以抑制肝脏糖异生,通过抑制 p38 MAPK 并激活 Nrf2 通路保护胰腺 β 细胞抵抗氧化损伤,通过抑制 IL-6/JAK/STAT3 信号通路抑制细胞凋亡 (apoptosis) 以改善肠道黏膜炎症,并通过激活大麻素 2 受体 (CB2R) 降低痛觉敏感性、缓解焦虑样行为,可用于 2 型糖尿病、溃疡性结肠炎及伴有焦虑的慢性炎症疼痛的相关研究。
产品编号: MS-U59948 纯度: 98.61% CAS No.: 13476-25-0 分子式: C15H16O4 分子量: 260.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Linderane 是一种口服有效且可穿过血脑屏障的天然倍半萜内酯,它通过激活 ERK/STAT3 间接激活 PDE3,进而抑制 cAMP/PKA/CREB 信号通路以抑制肝脏糖异生,通过抑制 p38 MAPK 并激活 Nrf2 通路保护胰腺 β 细胞抵抗氧化损伤,通过抑制 IL-6/JAK/STAT3 信号通路抑制细胞凋亡 (apoptosis) 以改善肠道黏膜炎症,并通过激活大麻素 2 受体 (CB2R) 降低痛觉敏感性、缓解焦虑样行为,可用于 2 型糖尿病、溃疡性结肠炎及伴有焦虑的慢性炎症疼痛的相关研究。

生物实验数据

生物活性 Linderane is an orally effective natural sesquiterpene lactone capable of crossing the blood-brain barrier that inhibits hepatic gluconeogenesis by indirectly activating PDE3 through ERK/STAT3 activation, thereby suppressing the cAMP/PKA/CREB signaling pathway, protects pancreatic β cells against oxidative damage by inhibiting p38 MAPK and activating the Nrf2 pathway, suppresses apoptosis by inhibiting the IL-6/JAK/STAT3 signaling pathway to ameliorate intestinal mucosal inflammation, and reduces pain sensitivity and alleviates anxiety-like behavior by activating the cannabinoid 2 receptor (CB2R), making it applicable for research on type 2 diabetes, ulcerative colitis, and chronic inflammatory pain accompanied by anxiety.
IC50 & Target

CYP2

 

体外研究
(In Vitro)

Linderane (2.5-20 µM; 5.5 h) 可在基础状态和毛喉素 (Forskolin) (MS-U03874) 刺激状态下,以剂量依赖方式抑制大鼠原代肝细胞的糖异生,并降低 Pck1 和 G6pc 的表达,且该效应依赖于 PDE3 的激活。
Linderane (2.5-20 µM; 2 h) 可在基础状态和福司柯林 (Forskolin) (MS-U03874) 刺激状态下,以剂量和时间依赖的方式降低大鼠原代肝细胞内的 cAMP 浓度并抑制 CREB 的磷酸化,且该效应依赖于 PDE3 的激活。
Linderane (10-20 µM) 可间接提高大鼠原代肝细胞中总 PDE 及 PDE3 的活性 (但不影响 PDE4 活性),对纯化的 PDE 酶无直接作用。
Linderane (2.5-20 µM; 2 h) 在大鼠原代肝细胞中通过 ERK/STAT3 通路间接激活 PDE3,该通路介导其对 cAMP 蓄积和糖异生的抑制作用。
Linderane (5-20 μM; 24 h) 不会损伤未处理的 INS-1 胰岛 β 细胞的活力,但在 40 μM 时会降低其活力。
Linderane (5-20 μM; 14 h) 可显著改善链脲佐菌素 (STZ) (MS-Q80520) 诱导的 INS-1 胰岛 β 细胞的存活率。
Linderane (5-20 μM; 14 h) 可显著恢复链脲佐菌素 (STZ) 诱导的 INS-1 胰腺 β 细胞的胰岛素分泌。
Linderane (5-20 μM; 14 h) 可显著降低链脲佐菌素 (STZ) 诱导的 INS-1 胰腺 β 细胞的凋亡水平。
Linderane (5-20 μM; 14 h) 可逆转 STZ 诱导的 bax 和 bcl-2 表达变化,从而减少 INS-1 胰岛 β 细胞的凋亡。
Linderane (5-20 μM; 14 h) 可显著抑制 STZ 诱导的 INS-1 胰岛 β 细胞中 p38 MAPK 通路的激活。
Linderane (5-20 μM; 14 h) 可显著增强链脲佐菌素 (STZ) 诱导的 INS-1 胰岛 β 细胞中 Nrf2 信号通路的激活。
Linderane (5-20 μM; 14 h) 可显著抑制链脲佐菌素 (STZ) 诱导的 INS-1 胰岛 β 细胞内活性氧 (ROS) 生成。
Linderane (5-20 μM; 14 h) 可显著恢复链脲佐菌素 (STZ) 诱导的 INS-1 胰腺 β 细胞中抗氧化酶 SOD、CAT 和 GPx 的活性。
Linderane (12.5-50 μM; 48 h) 可呈剂量依赖性抑制 LPS (MS-X54539) 刺激的 RAW264.7 巨噬细胞中 IL-6 的产生及炎症反应。
Linderane (3-25 μM) 可剂量依赖性地抑制 IL-6/STAT3 信号通路,并减弱小鼠淋巴细胞中 IL-6 介导的凋亡抵抗。
Linderane (2.5-10 μM; 3-5 days) 可有效抑制从 C57BL/6 小鼠脾细胞中分离的初始 CD4+ T 细胞向 Th17 细胞分化。
Linderane (2.5-10 μM; 3-4 days) 对从 C57BL/6 小鼠脾细胞中分离的初始 CD4+ T 细胞向 Treg 细胞的分化无显著影响。
Linderane (0.1-10 μM; 24 h) 可剂量依赖性地抑制 LPS 诱导小鼠 BV2 小胶质细胞释放 IL-6、TNF-α 和 IL-1β,在 24 h 后 0.1、1 和 10 μM 浓度下观察到显著效应。
Linderane (10 μM; 24 h) 可促进经 LPS 刺激的小鼠 BV2 小胶质细胞在 24 h 后从促炎 M1 表型向抗炎 M2 表型极化。

Cell Viability Assay

Cell Line: untreated INS-1 pancreatic β cells
Concentration: 5, 10, 20 and 40 μM
Incubation Time: 24 h
Result: Did not significantly alter cell viability at 5, 10, and 20 μM relative to control cells.
Caused a significant reduction in cell viability at 40 μM relative to control cells.

Cell Viability Assay

Cell Line: STZ-induced INS-1 pancreatic β cells
Concentration: 5, 10 and 20 μM
Incubation Time: 2 h pre-incubation, followed by 12 h co-exposure with 3 mM STZ
Result: Significantly improved cell viability compared to STZ-only treated cells, with a dose-dependent trend.

ELISA Assay

Cell Line: STZ-induced INS-1 pancreatic β cells
Concentration: 5, 10 and 20 μM
Incubation Time: 2 h pre-incubation, followed by 12 h co-exposure with 3 mM STZ; 30 min incubation with glucose-containing solution post-treatment
Result: Significantly increased insulin secretion compared to STZ-only treated cells, with a dose-dependent trend.

Apoptosis Analysis

Cell Line: STZ-induced INS-1 pancreatic β cells
Concentration: 5, 10 and 20 μM
Incubation Time: 2 h pre-incubation, followed by 12 h co-exposure with 3 mM STZ; 20 min staining at room temperature
Result: Significantly decreased the apoptotic rate compared to STZ-only treated cells, with a dose-dependent reduction.

Western Blot Analysis

Cell Line: STZ-induced INS-1 pancreatic β cells
Concentration: 5-20 μM
Incubation Time: 2 h pre-incubation, followed by 12 h co-exposure with 3 mM STZ
Result: Significantly reduced bax expression and increased bcl-2 expression compared to STZ-only treated cells, with a dose-dependent trend.\nSignificantly reduced p-p38 expression compared to STZ-only treated cells, with a dose-dependent reduction in the p-p38/p38 ratio.\nSignificantly increased nuclear Nrf2 and HO-1 expression compared to STZ-only treated cells, with a dose-dependent trend.

ELISA Assay

Cell Line: LPS-stimulated mouse BV2 microglial cells
Concentration: 0.1, 1 and 10 μM
Incubation Time: 24 h
Result: Dose-dependently reduced LPS-induced increases in IL-6, TNF-α, and IL-1β levels in cell supernatants.
Significantly lowered all three cytokine levels at 10 μM compared to the LPS-only group.

Western Blot Analysis

Cell Line: LPS-stimulated mouse BV2 microglial cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Induced reduction in iNOS levels and increase in Arg-1 levels in LPS-stimulated BV2 cells, which were reversed by cotreatment with CB2R antagonist SR144528 (MS-F64350).
体内研究
(In Vivo)

Linderane (50 mg/kg;口服;单次给药) 可通过 ERK/STAT3 通路激活健康雄性 C57BL/6J 小鼠肝脏中的 PDE,并抑制肝脏 cAMP/PKA/CREB 通路。
Linderane (50 mg/kg;口服;每日 2 次;连续 20 天) 可改善 2 型糖尿病雄性 ob/ob 小鼠的糖脂代谢,抑制肝脏糖异生基因的表达。
Linderane (慢性给药) 可改善 2 型糖尿病 ob/ob 小鼠的糖脂代谢。
Linderane (50-100 mg/kg;口服;每日一次;连续 8 天) 可缓解 DSS (MS-A45736) 诱导的雄性 C57BL/6J 小鼠溃疡性结肠炎的临床症状与组织病理学损伤。
Linderane (50 mg/kg;灌胃;每日一次;14 天) 可缓解雄性 C57BL/6 小鼠中由 CFA (MS-E83942) 诱导的慢性炎性疼痛及相关焦虑样行为,降低促炎细胞因子水平,并减弱 ACC 小胶质细胞的活化。

Animal Model: C57BL/6J (male, 8-9 weeks old)
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Elevated hepatic total PDE activity by 33.7%.
Reduced hepatic cAMP concentration.
Increased hepatic phosphorylation of ERK1/2 and STAT3.
Reduced hepatic phosphorylation of CREB.
Animal Model: B6.V-Lep^ob/Lep^ob (ob/ob) (male, 6-7 weeks old, genetically obese/type 2 diabetic)
Dosage: 50 mg/kg
Administration: p.o.; twice daily; 20 days
Result: Reduced random-fed blood glucose by 49.4% and fast blood glucose by 30.2% after 20 days.
Showed a trend toward reduced HbA1c levels (p=0.066).
Reduced serum triglyceride levels by 26.9% and hepatic triglyceride levels by 28.5%.
Left body weight unchanged.
Reduced hepatic Pck1 mRNA expression by 42.2% and hepatic G6pc mRNA expression by 42.6%.
Showed a trend toward a 28.3% increase in hepatic total PDE activity (p=0.081).
Reduced hepatic cAMP concentration by 22.6%.
Increased hepatic phosphorylation of ERK1/2 and STAT3.
Reduced hepatic phosphorylation of CREB.
Animal Model: C57BL/6J (male, 7 weeks old, ulcerative colitis induced by 2.5% w/v DSS in drinking water for 8 days)
Dosage: 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 8 days
Result: Reduced weight loss, improved stool consistency, reduced hematochezia, and significantly increased colon length compared to model control.
Decreased spleen size and spleen index compared to model control.
Significantly reduced proportions of Th17, Treg, and B lymphocytes, and increased percentage of T lymphocytes in mesenteric lymph nodes at 100 mg/kg dose compared to model control.
Attenuated epithelial damage, reduced ulcer number/size, and decreased immune cell infiltration compared to model control.
Downregulated proinflammatory genes including Il1b, Il6, Tnf, Ccl11, Cxcl1, and S100a8, and significantly suppressed STAT3 phosphorylation in colonic tissue at 100 mg/kg dose compared to model control.
Animal Model: C57BL/6 (male, 6−8 weeks old, 18 g)
Dosage: 50 mg/kg
Administration: i.g.; once daily; 14 days
Result: Increased mechanical pain threshold to ~2.5 g by day 14, thermal pain threshold to ~15 s by day 14, and reduced hind paw swelling to ~0.25 cm by day 14; these effects were significantly weakened by pre-administration of CB2R antagonist SR144528.
Increased OFT central region time to ~150 s and distance to ~1200 cm, and increased EPM open arm entries to ~12, time spent to ~70 s, and distance to ~200 cm; these anxiolytic effects were significantly weakened by pre-administration of CB2R antagonist SR144528.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 260.29
分子式 C15H16O4
CAS No. 13476-25-0

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 5 mg/mL (19.21 mM), Suspension.
10% DMSO+90% Corn Oil: 2 mg/mL (7.68 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (384.19 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.8419 mL19.2093 mL38.4187 mL96.0467 mL
5 mM0.7684 mL3.8419 mL7.6837 mL19.2093 mL
10 mM0.3842 mL1.9209 mL3.8419 mL9.6047 mL
15 mM0.2561 mL1.2806 mL2.5612 mL6.4031 mL
20 mM0.1921 mL0.9605 mL1.9209 mL4.8023 mL
25 mM0.1537 mL0.7684 mL1.5367 mL3.8419 mL
30 mM0.1281 mL0.6403 mL1.2806 mL3.2016 mL
40 mM0.0960 mL0.4802 mL0.9605 mL2.4012 mL
50 mM0.0768 mL0.3842 mL0.7684 mL1.9209 mL
60 mM0.0640 mL0.3202 mL0.6403 mL1.6008 mL
80 mM0.0480 mL0.2401 mL0.4802 mL1.2006 mL
100 mM0.0384 mL0.1921 mL0.3842 mL0.9605 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础